SOLVHealthcare · Medical Instruments & SuppliesThe 15 Wall Street analysts covering Solventum Corp. hold a median 12-month price target of $100 — +20.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 26 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Solventum Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.
Accruals (54): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SOLV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +20.5% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | BTIG | Reiterates | Buy | $95 |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 6 Aug 2026 | BTIG | Maintains | Buy | $91 → $95 |
| 6 Aug 2026 | Keybanc | Maintains | Overweight | — |
| 6 Aug 2026 | Keybanc | Maintains | Overweight | $93 → $102 |
| 6 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 6 Aug 2026 | Piper Sandler | Maintains | Overweight | $92 → $105 |
| 6 Aug 2026 | Stifel | Maintains | Buy | — |
| 6 Aug 2026 | Stifel | Maintains | Buy | $90 → $100 |
| 6 Aug 2026 | UBS | Maintains | Buy | — |
| 6 Aug 2026 | UBS | Maintains | Buy | $95 → $101 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $94 → $101 |
| 28 July 2026 | UBS | Upgrade | Buy | $95 |
| 28 July 2026 | UBS | Upgrade | Buy | — |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 15 May 2026 | Wedbush | Initiates | Outperform | — |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
| 6 May 2026 | Keybanc | Maintains | Overweight | — |
| 6 May 2026 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SOLV appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Solventum Corp. returned +15.3% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 57% of US stocks
Cheaper than 55% of US stocks
Cheaper than 30% of US stocks
Cheaper than 19% of US stocks
Higher than 33% of US stocks
Higher than 39% of US stocks
Higher than 71% of US stocks
Higher than 64% of US stocks
Higher than 80% of US stocks
Higher than 89% of US stocks
Higher than 63% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Solventum Corp. has a market value of $14.6B and an enterprise value of $19.5B.
Revenue in the twelve months to 30 June 2026: $8.3B. The latest quarter grew 2.2% year on year.
Net income over the same four quarters: $1.4B, a 17.3% net margin.
Diluted earnings per share, trailing twelve months: $8.18.
Free cash flow in the twelve months to 30 June 2026: −$118.0M.
Trailing P/E: 10.5×; forward P/E: 11.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Solventum Corp. employs 20,584 people — $404K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Solventum Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Solventum received FDA clearance to combine Restrata Matrix with V.A.C. Therapy.
Why it matters — The clearance may expand wound care applications and support the company’s long-term growth, according to the excerpt.
Solventum announced that the FDA granted 510(k) clearance for the combined use of Restrata Synthetic Electrospun Fiber Matrix and Solventum V.A.C. Therapy.
Why it matters — The clearance brings together two wound-care technologies in one treatment approach, which Solventum says is intended to streamline care and support healing.
Solventum will release its third-quarter fiscal 2026 financial results on November 5, 2026, after U.S. financial markets close.
Why it matters — SOLV watchers can note the scheduled date for the company’s quarterly financial results.
Zacks Investment Research says Solventum has a strong history of earnings surprises and currently has two key ingredients associated with a likely beat in its next quarterly report.
Why it matters — SOLV watchers may note the article's favorable assessment of factors tied to the upcoming earnings report.
Zacks Investment Research highlights its Zacks Style Scores, a feature of Zacks Premium, as a tool for finding stocks across value, growth and momentum investing styles. The headline characterizes Solventum as a top value stock for the long term.
Why it matters — SOLV watchers may note the article’s value-stock framing and its reference to Zacks’ screening feature.
The 15 Wall Street analysts covering Solventum Corp. have a median 12-month price target of $100, with estimates ranging from $71 to $113. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Solventum Corp., 8 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Solventum Corp. 93 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Solventum Corp. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +20.5% from the last close, and Ticker Nerd's factor model ranks Solventum Corp. 93 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Solventum Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $71 to $113 over the next 12 months.
Solventum Corp. returned +15.3% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V.
The most recent item we track (Zacks Investment Research, 23 Oct 2026): "SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy". Solventum received FDA clearance to combine Restrata Matrix with V.A.C. Therapy.
Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, and medical electrodes. The Dental Solutions segment offers products used in restorative and orthodontic workflows, including brackets, aligners, cements, and bonding agents. Through Health Information Systems, Solventum supplies software and services that support physician documentation, coding automation, speech recognition, and data visualization for healthcare organizations. The company serves customers in the United States and internationally through direct sales, distribution, key account management, inside sales, and e-commerce. Headquartered in Eagan, Minnesota, Solventum focuses on technologies that support safer, more efficient healthcare delivery.
CEO Mr. Bryan C. Hanson · 20,584 employees · United States · https://www.solventum.com
